Share Price and Basic Stock Data
Last Updated: October 18, 2025, 9:01 pm
| PEG Ratio | 2.74 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lactose (India) Ltd operates in the pharmaceuticals sector, focusing on the manufacture and distribution of lactose products. The company’s sales have shown robust growth, increasing from ₹46 Cr in FY 2022 to ₹116 Cr in FY 2025, demonstrating a compounded annual growth rate (CAGR) of approximately 48%. The quarterly sales figures further highlight this upward trajectory, with the latest reported sales of ₹39.58 Cr for June 2025, a significant rise from ₹9.62 Cr in June 2022. Despite slight fluctuations in sales during the last few quarters, the overall trend remains positive, suggesting solid demand for its products. The company’s operational efficiency is reflected in its operating profit margin (OPM), which has varied but stood at 11.29% recently, indicating decent control over costs relative to revenue. Overall, Lactose (India) Ltd appears well-positioned to capitalize on the growing pharmaceutical market in India, supported by increasing sales and a diverse product portfolio.
Profitability and Efficiency Metrics
Profitability metrics for Lactose (India) Ltd indicate a mixed performance. The net profit for FY 2025 stood at ₹5 Cr, which reflects a notable improvement compared to ₹1 Cr in FY 2023. The earnings per share (EPS) also rose to ₹4.10 in FY 2025 from ₹0.96 in FY 2023, showcasing enhanced profitability on a per-share basis. However, the operating profit margin has demonstrated fluctuations, with the highest recorded at 27.95% in FY 2022, declining to 15% in FY 2025. The company’s return on equity (ROE) remained at 9.69%, while return on capital employed (ROCE) stood at 12.9%, indicating that the company is generating reasonable returns on shareholders’ investments. The interest coverage ratio (ICR) of 3.02x suggests that Lactose can comfortably meet its interest obligations, which is a positive indicator of financial stability. Nonetheless, the cash conversion cycle of 165 days raises some concerns regarding liquidity and operational efficiency, particularly in managing inventories and receivables.
Balance Sheet Strength and Financial Ratios
Lactose (India) Ltd’s balance sheet reflects a mixed picture of financial health. As of FY 2025, total borrowings increased to ₹57 Cr, while reserves soared to ₹46 Cr, indicating a growing equity base. The debt-to-equity ratio remains moderate at 0.95x, suggesting that the company is utilizing debt responsibly. However, the long-term debt-to-equity ratio of 0.44x indicates a lower reliance on long-term borrowings, which is a strength. The current ratio of 1.28x and quick ratio of 0.73x indicate that the company has sufficient short-term assets to cover its liabilities, although the quick ratio suggests potential liquidity constraints. The price-to-book value (P/BV) ratio of 1.90x indicates that the stock might be trading at a premium relative to its book value, which could reflect investor confidence in the company’s growth prospects. Overall, the balance sheet indicates a solid financial foundation, but careful monitoring of liabilities is essential to maintain flexibility.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lactose (India) Ltd illustrates a stable ownership structure, with promoters holding 53.65% of the shares, which indicates strong control and confidence in the company’s direction. The public holds 45.73%, while domestic institutional investors (DIIs) account for 0.62%. Notably, foreign institutional investors (FIIs) are not reported, which could reflect a lack of international interest. The total number of shareholders stood at 17,013, indicating a broad base of retail investors. The stability in promoter holding over the past quarters suggests confidence in the company’s long-term strategy, while the modest institutional interest might point to potential growth opportunities to attract more institutional capital. This stable shareholding structure, combined with improving financial performance, could foster further investor confidence in the market.
Outlook, Risks, and Final Insight
If margins sustain and the company continues its revenue growth trajectory, Lactose (India) Ltd could enhance its market position in the pharmaceutical sector. However, risks remain, including potential fluctuations in raw material costs that could impact profit margins, and the relatively high cash conversion cycle, which may strain liquidity. Additionally, the company’s dependence on domestic markets poses risks associated with regulatory changes and competition. If Lactose effectively manages its operational efficiencies and capitalizes on its growing sales, it could see improved profitability and attract greater institutional interest. Furthermore, maintaining a balanced approach to leverage while ensuring liquidity will be crucial for sustaining growth. Overall, Lactose (India) Ltd appears well-positioned to navigate the challenges of the pharmaceutical industry, provided it remains agile and responsive to market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lactose (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.62 | 13.17 | 17.02 | 25.99 | 27.47 | 24.43 | 32.60 | 29.40 | 29.46 | 30.45 | 28.72 | 27.77 | 39.58 |
| Expenses | 7.34 | 10.82 | 14.29 | 21.99 | 23.70 | 21.04 | 26.88 | 23.28 | 23.88 | 25.44 | 25.75 | 24.36 | 35.11 |
| Operating Profit | 2.28 | 2.35 | 2.73 | 4.00 | 3.77 | 3.39 | 5.72 | 6.12 | 5.58 | 5.01 | 2.97 | 3.41 | 4.47 |
| OPM % | 23.70% | 17.84% | 16.04% | 15.39% | 13.72% | 13.88% | 17.55% | 20.82% | 18.94% | 16.45% | 10.34% | 12.28% | 11.29% |
| Other Income | 0.23 | 0.20 | 0.16 | 0.14 | 0.28 | 0.26 | 0.28 | 0.31 | 0.22 | 0.30 | 0.56 | 0.37 | 0.41 |
| Interest | 1.24 | 1.31 | 1.55 | 1.84 | 1.55 | 1.31 | 1.21 | 1.17 | 1.26 | 1.37 | 1.64 | 1.84 | 1.22 |
| Depreciation | 1.16 | 1.17 | 1.17 | 1.19 | 1.19 | 1.20 | 1.20 | 1.63 | 1.31 | 1.33 | 1.35 | 1.39 | 1.37 |
| Profit before tax | 0.11 | 0.07 | 0.17 | 1.11 | 1.31 | 1.14 | 3.59 | 3.63 | 3.23 | 2.61 | 0.54 | 0.55 | 2.29 |
| Tax % | 18.18% | -14.29% | 11.76% | 20.72% | 26.72% | 28.95% | 27.02% | 33.88% | 29.72% | 22.22% | 59.26% | -18.18% | 34.50% |
| Net Profit | 0.09 | 0.09 | 0.14 | 0.89 | 0.96 | 0.81 | 2.63 | 2.40 | 2.27 | 2.03 | 0.22 | 0.64 | 1.50 |
| EPS in Rs | 0.07 | 0.07 | 0.11 | 0.71 | 0.76 | 0.64 | 2.09 | 1.91 | 1.80 | 1.61 | 0.17 | 0.51 | 1.19 |
Last Updated: August 19, 2025, 12:44 pm
Below is a detailed analysis of the quarterly data for Lactose (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 39.58 Cr.. The value appears strong and on an upward trend. It has increased from 27.77 Cr. (Mar 2025) to 39.58 Cr., marking an increase of 11.81 Cr..
- For Expenses, as of Jun 2025, the value is 35.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.36 Cr. (Mar 2025) to 35.11 Cr., marking an increase of 10.75 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.47 Cr.. The value appears strong and on an upward trend. It has increased from 3.41 Cr. (Mar 2025) to 4.47 Cr., marking an increase of 1.06 Cr..
- For OPM %, as of Jun 2025, the value is 11.29%. The value appears to be declining and may need further review. It has decreased from 12.28% (Mar 2025) to 11.29%, marking a decrease of 0.99%.
- For Other Income, as of Jun 2025, the value is 0.41 Cr.. The value appears strong and on an upward trend. It has increased from 0.37 Cr. (Mar 2025) to 0.41 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 1.22 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.84 Cr. (Mar 2025) to 1.22 Cr., marking a decrease of 0.62 Cr..
- For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.39 Cr. (Mar 2025) to 1.37 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.55 Cr. (Mar 2025) to 2.29 Cr., marking an increase of 1.74 Cr..
- For Tax %, as of Jun 2025, the value is 34.50%. The value appears to be increasing, which may not be favorable. It has increased from -18.18% (Mar 2025) to 34.50%, marking an increase of 52.68%.
- For Net Profit, as of Jun 2025, the value is 1.50 Cr.. The value appears strong and on an upward trend. It has increased from 0.64 Cr. (Mar 2025) to 1.50 Cr., marking an increase of 0.86 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.19. The value appears strong and on an upward trend. It has increased from 0.51 (Mar 2025) to 1.19, marking an increase of 0.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 12:50 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 127 |
| Expenses | 21 | 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 111 |
| Operating Profit | 1 | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 16 |
| OPM % | 5% | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 13% |
| Other Income | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 6 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 0 | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 6 |
| Tax % | 60% | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | |
| Net Profit | 0 | 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 4 |
| EPS in Rs | 0.04 | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.10 | 3.48 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -133.33% | 200.00% | -100.00% | 200.00% | -50.00% | 600.00% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 333.33% | -300.00% | 300.00% | -250.00% | 650.00% | -628.57% |
Lactose (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 36% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 136% |
| 3 Years: | 29% |
| TTM: | -46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 39% |
| 3 Years: | 20% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:55 pm
Balance Sheet
Last Updated: August 11, 2025, 4:19 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 |
| Borrowings | 23 | 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 |
| Other Liabilities | 22 | 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 |
| Total Liabilities | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 |
| Fixed Assets | 28 | 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 |
| CWIP | 15 | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 16 | 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 |
| Total Assets | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 |
Below is a detailed analysis of the balance sheet data for Lactose (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
- For Reserves, as of Mar 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2024) to 46.00 Cr., marking an increase of 11.00 Cr..
- For Borrowings, as of Mar 2025, the value is 57.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 39.00 Cr. (Mar 2024) to 57.00 Cr., marking an increase of 18.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2024) to 18.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 32.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 55.00 Cr. (Mar 2024) to 52.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 10.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 71.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 101.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 32.00 Cr..
However, the Borrowings (57.00 Cr.) are higher than the Reserves (46.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -22.00 | -34.00 | -27.00 | -23.00 | -32.00 | -26.00 | -30.00 | -40.00 | -29.00 | -27.00 | -20.00 | -40.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 |
| Inventory Days | 69 | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 |
| Days Payable | 308 | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 |
| Cash Conversion Cycle | -114 | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 |
| Working Capital Days | -59 | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 |
| ROCE % | -3% | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.10 | 5.39 | 0.96 | 2.10 | -2.40 |
| Diluted EPS (Rs.) | 4.06 | 5.39 | 0.96 | 2.10 | -2.40 |
| Cash EPS (Rs.) | 8.38 | 9.54 | 4.68 | 5.57 | 1.64 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Revenue From Operations / Share (Rs.) | 92.46 | 90.47 | 52.26 | 36.49 | 30.57 |
| PBDIT / Share (Rs.) | 14.63 | 15.98 | 9.61 | 10.20 | 5.71 |
| PBIT / Share (Rs.) | 10.34 | 11.84 | 5.89 | 6.58 | 1.90 |
| PBT / Share (Rs.) | 5.50 | 7.68 | 1.16 | 2.52 | -2.86 |
| Net Profit / Share (Rs.) | 4.10 | 5.39 | 0.96 | 1.95 | -2.17 |
| PBDIT Margin (%) | 15.81 | 17.66 | 18.38 | 27.95 | 18.69 |
| PBIT Margin (%) | 11.18 | 13.08 | 11.26 | 18.02 | 6.22 |
| PBT Margin (%) | 5.94 | 8.48 | 2.22 | 6.89 | -9.35 |
| Net Profit Margin (%) | 4.43 | 5.96 | 1.83 | 5.33 | -7.08 |
| Return on Networth / Equity (%) | 8.78 | 14.41 | 2.97 | 6.23 | -7.06 |
| Return on Capital Employeed (%) | 14.70 | 19.78 | 9.85 | 10.99 | 2.83 |
| Return On Assets (%) | 3.86 | 6.73 | 1.18 | 2.71 | -2.80 |
| Long Term Debt / Equity (X) | 0.44 | 0.51 | 0.81 | 0.87 | 1.12 |
| Total Debt / Equity (X) | 0.95 | 0.80 | 0.95 | 1.04 | 1.20 |
| Asset Turnover Ratio (%) | 0.99 | 1.12 | 0.68 | 0.51 | 0.40 |
| Current Ratio (X) | 1.28 | 1.40 | 1.41 | 1.53 | 1.69 |
| Quick Ratio (X) | 0.73 | 0.73 | 0.55 | 1.05 | 0.97 |
| Inventory Turnover Ratio (X) | 2.93 | 2.47 | 2.37 | 0.72 | 0.53 |
| Interest Coverage Ratio (X) | 3.02 | 3.84 | 2.03 | 2.51 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.85 | 2.30 | 1.20 | 1.48 | 0.54 |
| Enterprise Value (Cr.) | 162.92 | 211.83 | 93.28 | 114.35 | 69.83 |
| EV / Net Operating Revenue (X) | 1.40 | 1.86 | 1.42 | 2.49 | 2.00 |
| EV / EBITDA (X) | 8.85 | 10.53 | 7.71 | 8.91 | 10.68 |
| MarketCap / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| Price / BV (X) | 1.90 | 3.73 | 1.37 | 1.92 | 0.87 |
| Price / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| EarningsYield | 0.04 | 0.03 | 0.02 | 0.03 | -0.08 |
After reviewing the key financial ratios for Lactose (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.06, marking a decrease of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.38. This value is within the healthy range. It has decreased from 9.54 (Mar 24) to 8.38, marking a decrease of 1.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 92.46. It has increased from 90.47 (Mar 24) to 92.46, marking an increase of 1.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 14.63, marking a decrease of 1.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.34. This value is within the healthy range. It has decreased from 11.84 (Mar 24) to 10.34, marking a decrease of 1.50.
- For PBT / Share (Rs.), as of Mar 25, the value is 5.50. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.50, marking a decrease of 2.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.10. This value is within the healthy range. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For PBDIT Margin (%), as of Mar 25, the value is 15.81. This value is within the healthy range. It has decreased from 17.66 (Mar 24) to 15.81, marking a decrease of 1.85.
- For PBIT Margin (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 11.18, marking a decrease of 1.90.
- For PBT Margin (%), as of Mar 25, the value is 5.94. This value is below the healthy minimum of 10. It has decreased from 8.48 (Mar 24) to 5.94, marking a decrease of 2.54.
- For Net Profit Margin (%), as of Mar 25, the value is 4.43. This value is below the healthy minimum of 5. It has decreased from 5.96 (Mar 24) to 4.43, marking a decrease of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.78. This value is below the healthy minimum of 15. It has decreased from 14.41 (Mar 24) to 8.78, marking a decrease of 5.63.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.70. This value is within the healthy range. It has decreased from 19.78 (Mar 24) to 14.70, marking a decrease of 5.08.
- For Return On Assets (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has decreased from 6.73 (Mar 24) to 3.86, marking a decrease of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 0.95, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.99. It has decreased from 1.12 (Mar 24) to 0.99, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.40 (Mar 24) to 1.28, marking a decrease of 0.12.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.73.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.93. This value is below the healthy minimum of 4. It has increased from 2.47 (Mar 24) to 2.93, marking an increase of 0.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 3.84 (Mar 24) to 3.02, marking a decrease of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 3. It has decreased from 2.30 (Mar 24) to 1.85, marking a decrease of 0.45.
- For Enterprise Value (Cr.), as of Mar 25, the value is 162.92. It has decreased from 211.83 (Mar 24) to 162.92, marking a decrease of 48.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.40, marking a decrease of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has decreased from 10.53 (Mar 24) to 8.85, marking a decrease of 1.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For Price / BV (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 3.73 (Mar 24) to 1.90, marking a decrease of 1.83.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lactose (India) Ltd:
- Net Profit Margin: 4.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.7% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.78% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.6 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.5,6,7A, Village Poicha (Rania), Vadodra District Gujarat 391780 | lil@lactoseindialimited.com http://www.lactoseindialimited.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Maheshwari | Managing Director |
| Mrs. Sangita Maheshwari | WholeTime Director & CFO |
| Mr. Pramod Kalani | Ind. Non-Executive Director |
| Mr. G K Sarda | Ind. Non-Executive Director |
| Mr. Dhaval Jayant Soni | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Lactose (India) Ltd?
Lactose (India) Ltd's intrinsic value (as of 18 October 2025) is 124.07 which is 6.04% higher the current market price of 117.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 148 Cr. market cap, FY2025-2026 high/low of 247/84.3, reserves of ₹46 Cr, and liabilities of 133 Cr.
What is the Market Cap of Lactose (India) Ltd?
The Market Cap of Lactose (India) Ltd is 148 Cr..
What is the current Stock Price of Lactose (India) Ltd as on 18 October 2025?
The current stock price of Lactose (India) Ltd as on 18 October 2025 is 117.
What is the High / Low of Lactose (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lactose (India) Ltd stocks is 247/84.3.
What is the Stock P/E of Lactose (India) Ltd?
The Stock P/E of Lactose (India) Ltd is 33.6.
What is the Book Value of Lactose (India) Ltd?
The Book Value of Lactose (India) Ltd is 46.7.
What is the Dividend Yield of Lactose (India) Ltd?
The Dividend Yield of Lactose (India) Ltd is 0.00 %.
What is the ROCE of Lactose (India) Ltd?
The ROCE of Lactose (India) Ltd is 12.9 %.
What is the ROE of Lactose (India) Ltd?
The ROE of Lactose (India) Ltd is 9.69 %.
What is the Face Value of Lactose (India) Ltd?
The Face Value of Lactose (India) Ltd is 10.0.